Stock listing

Liquidia Corporation

Selected listing: LT4 · DUS · EUR · DE

Liquidia Corporation (Dusseldorf:LT4), Health Technology. Latest release Sep 30, 2026: Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent.

LT4:DUSEURDEUpdated October 2, 2026

Ticker: Dusseldorf:LT4
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Dusseldorf
Currency: EUR

About Liquidia Corporation

The company focuses on developing and commercializing innovative therapies for patients with serious diseases. Liquidia aims to improve treatment options and outcomes through its proprietary technologies.

Latest news from Liquidia Corporation

Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent

September 30, 2026

Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent

September 29, 2026

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

September 3, 2026

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

September 2, 2026

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

September 1, 2026

All Liquidia Corporation news →

Events

Replays

Liquidia Corporation (LQDA) Q2 2026 Earnings Call
Wed, Aug 12, 2026 · 08:30 AM ET
Watch
Liquidia Corporation (LQDA) Q1 2026 Earnings Call
Mon, May 11, 2026 · 08:30 AM ET
Watch
Liquidia Corporation (LQDA) Q4 2025 Earnings Call
Thu, Mar 05, 2026 · 08:30 AM ET
Watch

Research Liquidia Corporation

Liquidia Corporation company profile

View the public company page for Liquidia Corporation on 6ix.

Liquidia Corporation news

Read company news and market updates connected to Liquidia Corporation.

Liquidia Corporation investor events

Find investor webinars, events, and replay context for Liquidia Corporation.